The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) -- as well as three neonatal fragment ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, targeted therapies, and surgery techniques.

The Idiopathic Thrombocytopenic Purpura market is poised for significant expansion through 2032, underpinned by rising disease awareness, improving epidemiological understanding, and a vibrant ...

RGS12 selectively accelerated the rate of reversal of the voltage-independent pathway mediated by tyrosine kinase, whereas the voltage-dependent pathway remained unaltered (Fig. 1b).

Lipid kinases are enzymes that play a critical role in both cell signaling and membrane trafficking by phosphorylating lipid ...

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on ...

Lipid kinases are enzymes that play a critical role in both cell signalling and membrane trafficking by phosphorylating lipid ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...